Relationship between microinflammatory state, intestinal flora characteristics and gastrointestinal dysfunction in patients with diabetes nephropathy

doi:10.3877/cma.j.issn.2095-2015.2025.06.007

Abstract

Abstract:

Objective

To explore the relationship between microinflammatory state and intestinal flora characteristics and gastrointestinal dysfunction in patients with diabetic nephropathy (DN).

Methods

A total of 130 cases of DN patients admitted to Hengshui Second People's Hospital from September 2022 to November 2024 were selected retrospectively as the observation group, and 86 volunteers who underwent health checkups in our hospital during the same period were selected as the control group. The general data, glycemic and lipid metabolism-related indexes [glycosylated hemoglobin (HbA1c), fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), low-density lipoproteins (LDL-C), high-density lipoproteins (HDL-C)] levels, serum inflammatory factors [interleukin-6 (IL-6), C-reactive protein (CRP)] levels, intestinal flora abundance, and the degree of gastrointestinal dysfunction [Gastrointestinal Symptom Rating Scale (GSRS)], and the relationship between patients' inflammatory factor levels and intestinal flora species was analyzed using Pearson correlation.

Results

The levels of body mass index, diastolic blood pressure, systolic blood pressure, HbA1c, FBG, TC, TG, LDL-C, HDL-C, IL-6, and CRP in the observation group were higher than those in the control group (P<0.05). The relative abundances of Bifidobacterium, Coriobacteriaceae(Red Stink Bug Bacteria Family), and Lactobacillusin the observation group were lower than those in the control group (P<0.05), while the relative abundances of Lachnospira, Coprococcus, Fusobacterium, and Ruminococcaceae were higher than those in the control group (P<0.05). The scores for abdominal pain, regurgitation, dyspepsia, diarrhea, and constipation in the GSRS of the observation group were higher than those in the control group (P<0.05). Pearson correlation analysis showed that serum IL-6 levels were positively correlated with the abundance of Ruminococcaceae, and negatively correlated with the abundances of Coriobacteriaceae, Lactobacillus, and Bifidobacterium (P<0.05). Serum CRP levels were positively correlated with the abundances of intestinal Fusobacterium, Ruminococcaceae, Coprococcus, and Lachnospira, and negatively correlated with the abundance of Coriobacteriaceae (P<0.05).

Conclusion

Patients with DN have an interaction of metabolic abnormalities, intestinal flora dysregulation and microinflammatory state, and their gastrointestinal dysfunction may be related to the above pathologic changes.

Key words: Diabetic nephropathy, Microinflammatory state, Intestinal flora characteristics, Gastrointestinal dysfunction

Wei Sun, Yuru Li, Yongzhen Guo, Nan Zhao. Relationship between microinflammatory state, intestinal flora characteristics and gastrointestinal dysfunction in patients with diabetes nephropathy[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(06): 594-598.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2025.06.007

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2025/V15/I06/594

Figures/Tables 6

References 23

[1]	Li D, Li H, Shi B, et al. Wogonin alleviates streptozotocin-stimulated diabetic nephropathy through its antidiabetic, antidyslipidemic, and antioxidative effects in rats[J]. Pharmacognosy Magazine, 2025, 21(1): 218-228.
[2]	Dharmian PJ, Claret APS, Ramakrishnan P, et al. Novel polyethyleneimine-chitosan nanoparticles encapsulating urolithin B: A potential nanotherapeutic approach for diabetic nephropathy[J]. Journal of Cluster Science, 2025, 36(2): 46-46.
[3]	Chen K, Gao Z, Wang H, et al. 385-P: MDSC-mediated neutrophil extracellular traps-based targeting of diabetic vasculopathy— Dapagliflozin for vascular remodeling in diabetic nephropathy[J]. Diabetes, 2024, 73(1): 385-390.
[4]	赵敏, 张菊, 李蓉, 等. 微炎症状态及肠道菌群与老年2型糖尿病患者并发糖尿病肾病的关系探讨[J]. 中国医刊, 2024, 59(8): 861-865.
[5]	Pasricha PJ, Mcknight MB, Villatoro L, et al. Joint hypermobility, autonomic dysfunction, gastrointestinal dysfunction, and autoimmune markers: Clinical associations and response to intravenous immunoglobulin therapy[J]. Am J Gastroenterol, 2024, 119(11): 10-19.
[6]	Chennakesavulu PV, Ingawale S, Mogga P, et al. S4744 Unlocking the digestive dilemma: Sevelamer's trail in gastrointestinal dysfunction and literature review[J]. Am J Gastroenterol, 2024, 119(10S): S3000.
[7]	中华医学会肾脏病学分会专家组. 糖尿病肾脏疾病临床诊疗中国指南[J]. 中华肾脏病杂志, 2021, 37(3): 255-304.
[8]	Komori S, Akiyama J, Tatsuno N, et al. Prevalence and risk factors of constipation symptoms among patients undergoing colonoscopy: A single-center cross-sectional study[J]. Digestion, 2024, 105(4): 299-309.
[9]	Atsuhiko S, Naoki S, Yuki O, et al. Dipeptidyl peptidase-4 inhibitor-related renal disease[J]. J Diabetes Complications, 2023, 37(10): 108590-108590.
[10]	Samar S, Meshari A, Nuha A, et al. Association of a single nucleotide polymorphism in SOD2 with susceptibility for the development of diabetic nephropathy in patients with type 2 diabetes: A Saudi population study[J]. Endocrinol Diabetes Metab, 2023, 6(6): e449-e449.
[11]	He G, Chen J, Hao W, et al. Causal effect of gut microbiota and diabetic nephropathy: A Mendelian randomization study[J]. Diabetol Metab Syndr, 2024, 16(1): 89-102.
[12]	Zadabbas H, Golbashirzadeh M, Moradzadegan A. Exploring Cystatin C as an Early Indicator of End-Stage Diabetic Nephropathy in Patients With Type 2 Diabetes[J]. J Endocrinol Metab, 2024, 14(5): 240-249.
[13]	Maqsood M, Sharif S, Naz S, et al. Expression of pro-inflammatory cytokines(IL-6 & IL-18) exacerbate the risk of diabetic nephropathy in the Pakistani population[J]. Mol Biol Rep, 2023, 50(4): 3249-3257.
[14]	Jiang T, Xia Y, Wang W, et al. Apoptotic bodies inhibit inflammation by PDL1–PD1-mediated macrophage metabolic reprogramming[J]. Cell Proliferation, 2024, 57(1): e13531-e13547.
[15]	Ni Y, Zheng L, Nan S, et al. Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota[J]. Acta Biochim Biophys Sin, 2022, 54(10): 1406-1420.
[16]	姚碧晴, 陈铖. 肠道菌群失调与糖尿病肾病的关系[J]. 中华实用诊断与治疗杂志, 2020, 34(1): 102-105.
[17]	Segui-Perez C, Huang LZX, Paganelli FL, et al. Probiotic Bifidobacterium bifidum strains desialylate MUC13 and increase intestinal epithelial barrier function[J]. Sci Rep, 2025, 15(1): 1-15.
[18]	Li XJ, Shan QY, Wu X, et al. Gut microbiota regulates oxidative stress and inflammation: A double-edged sword in renal fibrosis[J]. Cell Mol Life Sci, 2024, 81(1): 1-20.
[19]	Peng S, Liu M, Zeng Y, et al. Exploring the gut-inflammation connection: A Mendelian randomization study on gut microbiota, inflammatory factors, and uterine fibroids risk[J]. Medicine, 2024, 103(47): e40514.
[20]	Zheng X, Xia C, Liu M, et al. Role of folic acid in regulating gut microbiota and short-chain fatty acids based on an in vitro fermentation model[J]. Appl Microbiol Biotechnol, 2024, 108(1): 40.
[21]	Zhuang LG, Zhang R, Jin GX, et al. Asiaticoside improves diabetic nephropathy by reducing inflammation, oxidative stress, and fibrosis: An in vitro and in vivo study[J]. World J Diabetes, 2024, 15(10): 2111-2122.
[22]	Satheesan A, Kumar J, Leela KV, et al. Review on the role of nucleotide-binding oligomerization domain-like receptor protein 3(NLRP3) inflammasome pathway in diabetes: mechanistic insights and therapeutic implications[J]. Inflammopharmacology, 2024, 32(5): 2753-2779.
[23]	邢慧敏, 田美玲, 云聪, 等. 不同时期应用双歧杆菌三联活菌胶囊治疗妊娠糖尿病对患者肠道微生态及妊娠结局的影响[J]. 川北医学院学报, 2024, 39(4): 532-537.

组别	例数	性别[例(%)]		年龄(岁,±s)	体重指数(kg/m²,±s)	舒张压(mmHg,±s)	收缩压(mmHg,±s)
组别	例数	男	女	年龄(岁,±s)	体重指数(kg/m²,±s)	舒张压(mmHg,±s)	收缩压(mmHg,±s)
对照组	86	50(58.14)	36(41.86)	55.34±11.32	20.35±2.25	75.67±8.33	114.45±4.36
观察组	130	77(59.23)	53(40.77)	54.73±11.26	28.57±2.27	87.58±9.46	150.34±4.21
t/χ²值		0.025		0.388	26.143	9.490	60.467
P值		0.873		0.697	<0.001	<0.001	<0.001

组别	例数	性别[例(%)]		年龄(岁,±s)	体重指数(kg/m²,±s)	舒张压(mmHg,±s)	收缩压(mmHg,±s)
组别	例数	男	女	年龄(岁,±s)	体重指数(kg/m²,±s)	舒张压(mmHg,±s)	收缩压(mmHg,±s)
对照组	86	50(58.14)	36(41.86)	55.34±11.32	20.35±2.25	75.67±8.33	114.45±4.36
观察组	130	77(59.23)	53(40.77)	54.73±11.26	28.57±2.27	87.58±9.46	150.34±4.21
t/χ²值		0.025		0.388	26.143	9.490	60.467
P值		0.873		0.697	<0.001	<0.001	<0.001

组别	例数	糖化血红蛋白(%)	空腹血糖(mmol/L)	总胆固醇(mmol/L)	甘油三酯(mmol/L)	低密度脂蛋白胆固醇(mmol/L)	高密度脂蛋白胆固醇(mmol/L)
对照组	86	2.87±1.35	2.23±1.55	1.42±0.21	1.14±0.63	1.25±0.35	2.18±0.32
观察组	130	9.76±1.46	9.45±1.83	5.54±0.53	2.89±0.91	2.67±0.49	1.26±0.39
t值		34.973	30.125	68.572	15.534	24.827	18.193
P值		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

组别	例数	糖化血红蛋白(%)	空腹血糖(mmol/L)	总胆固醇(mmol/L)	甘油三酯(mmol/L)	低密度脂蛋白胆固醇(mmol/L)	高密度脂蛋白胆固醇(mmol/L)
对照组	86	2.87±1.35	2.23±1.55	1.42±0.21	1.14±0.63	1.25±0.35	2.18±0.32
观察组	130	9.76±1.46	9.45±1.83	5.54±0.53	2.89±0.91	2.67±0.49	1.26±0.39
t值		34.973	30.125	68.572	15.534	24.827	18.193
P值		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

组别	例数	白细胞介素-6(ng/L)	C反应蛋白(mg/L)
对照组	86	23.35±3.12	1.33±0.38
观察组	130	68.18±5.35	2.85±0.27
t值		70.180	34.358
P值		<0.001	<0.001

Please choose a citation manager

Content to export